A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

Eiichi Shiba,Hiroko Yamashita,Junichi Kurebayashi,Shinzaburo Noguchi,Hirotaka Iwase,Yasuo Ohashi,Kiyofumi Sasai,Tsukasa Fujimoto

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.

2016

Eiichi Shiba
Hiroko Yamashita
Junichi Kurebayashi
Shinzaburo Noguchi
Hirotaka Iwase
Yasuo Ohashi
Kiyofumi Sasai
Tsukasa Fujimoto

Background Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leuprorelin.

Keywords:

Randomized controlled trial
Breast cancer
Tamoxifen
Agonist
Adjuvant
Endocrine system
Survival rate
Oncology
Internal medicine
Leuprorelin
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations